The lipid metabolism transcription factor FOXO1 has a dual regulatory function in nonalcoholic fatty liver disease (NAFLD); overexpression of this factor in the liver can result in increased TG production, decreased hepatic lipid oxidation, and worsened lipoatrophy. This evidence concerns the gene FOXO1 and metabolic dysfunction-associated steatotic liver disease.